. 2019 Aug 15;10(8):3762–3773. doi: 10.19102/icrm.2019.100801

Table 2:

Randomized Controlled Trials of Prophylactic Catheter Ablation in SHD Patients

Trial	Study Group		Number of Patients Randomized	Ablation Strategy	Follow-up Time	Primary Endpoint	Outcomes
Reddy et al. 2007¹⁹	•	ICM	128	Substrate-based with mapping in sinus rhythm	22.5 ± 5.5 months	Survival free from ICD shocks	•	65% reduction in the rate of appropriate ICD therapy
Reddy et al. 2007¹⁹	•	Arms: ablation vs. ICD alone	128	Substrate-based with mapping in sinus rhythm	22.5 ± 5.5 months	Survival free from ICD shocks	•	65% reduction in the rate of appropriate ICD therapy
Sapp et al. 2016⁵⁷	•	ICM	259	Activation mapping targeting clinical VT vs. substrate-based approach	27.9 ± 17.1 months	Composite of death, VT storm, or appropriate ICD shock	•	Appropriate ICD shock was reduced by 28% with ablation (HR: 0.72, 95% CI: 0.53–0.98; p = 0.04)
Sapp et al. 2016⁵⁷	•	Arms: ablation vs. escalated antiarrhythmic drugs	259		27.9 ± 17.1 months	Composite of death, VT storm, or appropriate ICD shock	•
Di Biase et al. 2015⁷²	•	ICM	118	Clinical ablation with activation and entrainment mapping vs. substrate modification	12 months	Recurrence of VT	•	Extensive substrate-based ablation was superior to clinical target ablation
Di Biase et al. 2015⁷²	•	Arms: clinical target ablation vs. substrate-based ablation	118		12 months	Recurrence of VT	•
Tanner et al. 2010⁸³	•	ICM	110	Entrainment mapping ± pacemapping ± substrate modification	22.5 months	Time to first recurrence	•	18.6 months in the CA group vs. 5.9 months in the control group
Tanner et al. 2010⁸³	•	Arms: ablation vs. ICD alone	110	Entrainment mapping ± pacemapping ± substrate modification	22.5 months	Time to first recurrence	•	Freedom from VT/VF was 47% in the CA group and 29% in the control group (HR: 0.61, 95% CI: 0.37–0.99)
Dinov et al. 2014⁸⁵	•	ICM and NICM patients undergoing ablation	227	Activation and entrainment mapping with elimination of all clinically and nonclinically stable MMVT	12 months	Survival free of VT	•	No difference in short-term outcomes
Dinov et al. 2014⁸⁵	•	ICM and NICM patients undergoing ablation	227		12 months	Survival free of VT	•	VT-free survival in NIDCM was 40.5% vs. 57% in ICM
Kuck et al. 2017⁸⁶	•	ICM	111	Entrainment mapping ± pacemapping ± substrate modification	2.3 ± 1.1 years	Time to first recurrence of VT/VF	•	No difference in the time to first recurrence
Kuck et al. 2017⁸⁶	•	Arms: ablation vs. ICD alone	111	Entrainment mapping ± pacemapping ± substrate modification	2.3 ± 1.1 years	Time to first recurrence of VT/VF	•	CA resulted in a ; 50% reduction in total ICD interventions in the ablation group

CA: catheter ablation; CI: confidence interval; HR: hazard ratio; ICD: implantable cardioverter-defibrillator; ICM: ischemic cardiomyopathy; MMVT: monomorphic ventricular tachycardia; NICM: nonischemic cardiomyopathy; VT: ventricular tachycardia; VF: ventricular fibrillation.